Modified Vaccine for High Risk or Low Residual Melanoma Patients

Inclusion Criteria

• •1. Patients included in this protocol must carry one or more of the following tissue typing alleles: HLA-A2, -A24, -A33, -B35, -B49, -CW04/12(04/08). We estimate that 50% of melanoma patients will be eligible.
• •2. Cutaneous malignant melanoma AJCC stage IIb (\>4 mm) or IIc (ulcerated melanoma \>4mm).
• •3. Metastatic melanoma AJCC stage III (nodal involvement, N1-3a,b) post-surgical removal of lymph nodes.
• •4. Metastatic melanoma AJCC stage IV, completely resected.
• •5. Non-resectable metastatic melanoma of low burden disease and normal LDH who have undergone at least two treatment lines, including chemotherapy (DTIC, temodal, taxanes, platinum compounds), anti-CTLA-4 (ipilimumab) and B-RAF inhibitor if harboring the V600E BRAF mutation in their tumor.
• •6. Non cutaneous malignant melanoma of respective stages including uveal and mucosal melanoma.
• •7. Melanoma can be of either mutant or wild-type B-RAF.
• •8. Karnofsky performance status \> 80 (Normal activity with effort).
• •9. No active cardio-respiratory disease.
• •10. Not pregnant or nursing. Women must take contraceptives during the treatment period.Hematocrit \>25% and WBC \>3000.
• •11. Informed consent of the patient.